Cyclophosphamide protection in NZB/NZW disease. Mechanisms and therapeutic regimens.
Regular administration of cyclophosphamide to NZB/NZW female mice effectively protects against the nephritis that is thought to be a model for human SLE nephritis. Reductions in serologic, histologic, and immunogluorescent parameters of the disease are correlated. Intermittent as well as continuous administration of the drug is effective without the development of leukopenia. Possible mechanisms of drug action and a modified approach to therapy of immune complex disease are discussed.
D000818:Animals; D000974:Antibodies, Antinuclear / Q000032:analysis; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D004195:Disease Models, Animal; D005260:Female; D005921:Glomerulonephritis / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D006824:Hybridization, Genetic; D007105:Immune Complex Diseases / Q000235:genetics / Q000517:prevention & control*; D007962:Leukocytes / Q000187:drug effects; D051379:Mice; D008814:Mice, Inbred NZB / Q000276:immunology; D008815:Mice, Inbred Strains / Q000276:immunology
D000974:Antibodies, Antinuclear; D003520:Cyclophosphamide